OncoMatch/Clinical Trials/NCT05947487
CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors
Is NCT05947487 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies CD70-targeting CAR-T cells for solid tumor, adult.
Treatment: CD70-targeting CAR-T cells — In this single-center, single-arm,prospective, open-label, phase 1/2 study, the safety and efficacy of autologous CD70 targeted chimeric antigen receptor modified T (CAR-T) cell therapy will be evaluated in patients with CD70 antigen positive advanced/metastatic solid tumors . In this clinical trial, at least 12 eligible patients in dose escalation period will be enrolled to receive 3 doses of CD70-CAR cell therapy according to the "3+3" principle. In dose expansion period, additional at most 21 eligible patients will be enrolled to receive CD70-CAR-T cell therapy at dose of recommended phase 2 dose(RP2D).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Biomarker criteria
Required: CD70 antigen expression level ≥ 30% (≥ 30%)
CD70 antigen expression level ≥ 30%
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: any systemic therapy — first-line or more
failed to at least first-line treatment or initially diagnosed advanced/metastatic solid tumors that have no NCCN guideline recommended standard first-line therapy
Cannot have received: CD70-CAR T cell therapy
Previously received CD70-CAR T cell therapy
Cannot have received: cytotoxic chemotherapy
Exception: within 4 weeks or 5 half-lives before enrollment
Received cytotoxic chemicals, monoclonal antibodies, or immunotherapy within 4 weeks or 5 half-lives before enrollment
Cannot have received: monoclonal antibody
Exception: within 4 weeks or 5 half-lives before enrollment
Received cytotoxic chemicals, monoclonal antibodies, or immunotherapy within 4 weeks or 5 half-lives before enrollment
Cannot have received: immunotherapy
Exception: within 4 weeks or 5 half-lives before enrollment
Received cytotoxic chemicals, monoclonal antibodies, or immunotherapy within 4 weeks or 5 half-lives before enrollment
Lab requirements
Blood counts
anc ≥1.5x10^9/l; platelet count ≥75x10^9/l; hemoglobin ≥90 g/l
Kidney function
serum creatinine ≤1.5 x uln or creatinine clearance of ≥60 ml/min
Liver function
serum ast and serum alt ≤3.0 x uln (≤5 x uln for patients with liver cancer or metastases); total serum bilirubin ≤1.5 x uln (≤3 x uln for patients with liver cancer or metastases)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05947487 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CD70-CAR T cell therapy, cytotoxic chemotherapy, monoclonal antibody disqualifies patients from enrollment.
Does this trial require CD70?
Yes, CD70 antigen expression level ≥ 30% is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify